Evidence map›Paper›PMID 38392053›Full record

ArticleCurrent oncology (Toronto, Ont.)2024

Disruptions in Cancer Care Due to the COVID-19 Pandemic and Fear of Cancer Recurrence in Women with Breast Cancer: A Mixed-Methods Study.

Claudia Mc Brearty, Laurie Bisaillon, Michel Dorval, Hermann Nabi, Christine Desbiens, Julie Lemieux, Valérie Théberge, Amel Baghdadli, Sophie Lauzier, Josée Savard

Open access · goldAbstract read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Claudia Mc BreartySchool of Psychology, Université Laval, Quebec, QC G1V 0A6, Canada.
Laurie BisaillonSchool of Psychology, Université Laval, Quebec, QC G1V 0A6, Canada.
Michel DorvalUniversité Laval Cancer Research Center, Quebec, QC G1R 3S3, Canada.ORCID 0000-0002-3207-8211
Hermann NabiUniversité Laval Cancer Research Center, Quebec, QC G1R 3S3, Canada.ORCID 0000-0002-7832-0413
Christine DesbiensCentre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec, QC G1S 4L8, Canada.
Julie LemieuxCentre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec, QC G1S 4L8, Canada.
Valérie ThébergeCentre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec, QC G1S 4L8, Canada.
Amel BaghdadliCentre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec, QC G1S 4L8, Canada.
Sophie LauzierUniversité Laval Cancer Research Center, Quebec, QC G1R 3S3, Canada.
Josée SavardSchool of Psychology, Université Laval, Quebec, QC G1V 0A6, Canada.
Université Laval · CACentre hospitalier universitaire de Québec · CACentre intégré de santé et de services sociaux de Chaudière-Appalaches · CA

Funding

Fondation de l'Université Laval 9080Fonds de Recherche du Québec - Société et culture 2021-SE3-282466Pfizer (Canada) 68364811Unité Soutien SRAP du Québec 313085
6 · The paper itself

Abstract

objectiveThis study investigated if fear of cancer recurrence (FCR) levels and the proportion of women having a clinical level of FCR differed by whether women had or had not experienced disruptions in their cancer tests and treatments due to the pandemic.

methodsWe conducted a mixed-methods study between November 2020 and March 2021 among women diagnosed with breast cancer in the previous five years at the time of their entry in the study. Women completed a questionnaire online assessing disruptions in breast cancer tests and treatments due to the pandemic and the severity subscale of the Fear of Cancer Recurrence Inventory. Semi-structured interviews were also conducted with a subsample of 24 participants and were thematically analyzed.

resultsThe proportion of patients with a clinical level of FCR was significantly higher among those who experienced the postponement or cancellation of diagnostic and disease progression tests (e.g., blood tests, X-rays, or magnetic resonance imaging; adjusted PR = 1.27 95% CI = 1.13-1.43). Qualitative findings suggest that FCR was exacerbated by the pandemic context. In particular, perceived or actual barriers to care access due to the pandemic were identified as significant FCR-enhancing factors.

conclusionsThese results highlight the need to keep diagnostic and progression tests as timely as possible to prevent increases in FCR levels and offer counselling about FCR when postponing or cancellation are inevitable.

Indexed as

Breast NeoplasmsCOVID-19FearFemaleHumansNeoplasm Recurrence, LocalPandemicsSurvivorsbreast cancercancer care trajectoryCOVID-19fear of cancer recurrencepandemic

Identifiers

PMID38392053
PMCPMC10887748
OpenAlexW4391451233

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.